Vaccine efficacy in senescent mice challenged with recombinant SARS-CoV bearing epidemic and zoonotic spike variants
about
Animal models for SARS and MERS coronavirusesCoronavirus reverse genetic systems: infectious clones and repliconsHuman coronaviruses: insights into environmental resistance and its influence on the development of new antiseptic strategiesLack of innate interferon responses during SARS coronavirus infection in a vaccination and reinfection ferret modelAnimal models of Middle East respiratory syndrome coronavirus infectionSevere acute respiratory syndrome coronavirus as an agent of emerging and reemerging infectionMechanisms of GII.4 norovirus persistence in human populationsEvidence supporting a zoonotic origin of human coronavirus strain NL63Genomic characterization of severe acute respiratory syndrome-related coronavirus in European bats and classification of coronaviruses based on partial RNA-dependent RNA polymerase gene sequencesA decade after SARS: strategies for controlling emerging coronavirusesRapid generation of a mouse model for Middle East respiratory syndrome.Receptor-binding domain as a target for developing SARS vaccines.A mouse model for Betacoronavirus subgroup 2c using a bat coronavirus strain HKU5 variantImmune mechanisms responsible for vaccination against and clearance of mucosal and lymphatic norovirus infection.MyD88 is required for protection from lethal infection with a mouse-adapted SARS-CoV.Toll-like receptors, chemokine receptors and death receptor ligands responses in SARS coronavirus infected human monocyte derived dendritic cells.Coronaviruses post-SARS: update on replication and pathogenesis.Immunization with an attenuated severe acute respiratory syndrome coronavirus deleted in E protein protects against lethal respiratory disease.Allelic Variation in the Toll-Like Receptor Adaptor Protein Ticam2 Contributes to SARS-Coronavirus Pathogenesis in Mice.Comparative pathogenesis of three human and zoonotic SARS-CoV strains in cynomolgus macaquesThe emergence of the Middle East respiratory syndrome coronavirusMechanisms of severe acute respiratory syndrome pathogenesis and innate immunomodulation.The spike protein of SARS-CoV--a target for vaccine and therapeutic development.Effects of Toll-like receptor stimulation on eosinophilic infiltration in lungs of BALB/c mice immunized with UV-inactivated severe acute respiratory syndrome-related coronavirus vaccine.Immunization with SARS coronavirus vaccines leads to pulmonary immunopathology on challenge with the SARS virus.Virus-specific memory CD8 T cells provide substantial protection from lethal severe acute respiratory syndrome coronavirus infection.Successful vaccination strategies that protect aged mice from lethal challenge from influenza virus and heterologous severe acute respiratory syndrome coronavirus.Inhibitors of SARS-CoV entry--identification using an internally-controlled dual envelope pseudovirion assay.A double-inactivated severe acute respiratory syndrome coronavirus vaccine provides incomplete protection in mice and induces increased eosinophilic proinflammatory pulmonary response upon challengeToll-Like Receptor 3 Signaling via TRIF Contributes to a Protective Innate Immune Response to Severe Acute Respiratory Syndrome Coronavirus InfectionNatural mutations in the receptor binding domain of spike glycoprotein determine the reactivity of cross-neutralization between palm civet coronavirus and severe acute respiratory syndrome coronavirus.Potent cross-reactive neutralization of SARS coronavirus isolates by human monoclonal antibodies.Synthetic reconstruction of zoonotic and early human severe acute respiratory syndrome coronavirus isolates that produce fatal disease in aged mice.Altered pathogenesis of porcine respiratory coronavirus in pigs due to immunosuppressive effects of dexamethasone: implications for corticosteroid use in treatment of severe acute respiratory syndrome coronavirus.A live, impaired-fidelity coronavirus vaccine protects in an aged, immunocompromised mouse model of lethal disease.Mechanisms of zoonotic severe acute respiratory syndrome coronavirus host range expansion in human airway epithelium.Chimeric coronavirus-like particles carrying severe acute respiratory syndrome coronavirus (SCoV) S protein protect mice against challenge with SCoVStructural basis for potent cross-neutralizing human monoclonal antibody protection against lethal human and zoonotic severe acute respiratory syndrome coronavirus challengeRoadmap to developing a recombinant coronavirus S protein receptor-binding domain vaccine for severe acute respiratory syndromeA SARS-like cluster of circulating bat coronaviruses shows potential for human emergence.
P2860
Q26799857-47EB5EEE-3259-4757-B91A-A251310F64F6Q26863163-637B8F12-7276-4CA8-AF1A-C27CB67CC19BQ27011643-CF45C654-0B3D-4CD0-9F52-7D66CFD192D3Q27317179-E4C6D10A-A96E-4413-B441-AA9CA3E63B05Q28086778-06454F18-6B36-4725-8DB2-8B4E5BC30D23Q28383088-20BC3993-B827-451D-9984-249F95E5CACFQ28472177-BB44680C-DB57-4AF0-9A7C-2BADFFB5ACB7Q28712758-52D5F400-0803-4BBB-B71C-AC86302A0A16Q28748910-4AB4242A-2CC3-4F3E-9C50-EE4EFA83119EQ28817689-5291792B-3373-4144-830C-0741800128B9Q30217177-33304EC7-CDFD-4312-9170-D802C8F237E4Q30353170-D5958C38-22B4-47D8-A2E2-556B6F2A8FB4Q30360627-1D48D660-A142-4893-841C-6D7A01EE5ACBQ33392684-38867A7F-5D41-4A6C-B90B-A0840B944E7EQ33392688-77562FEC-A929-4028-8226-A020C03DDCF3Q33463837-60D3F3AD-7613-4685-9ABC-A9272073572AQ33694361-A2935040-5D32-4C4A-A02A-D9B0CF198041Q33695621-AAEB4904-E176-459C-9540-37AAB98034A8Q33807608-D620FE2C-6544-4C42-85B8-22B6AF7286CBQ33886371-E6DB2B88-CF64-4973-9F09-21370EDC51FEQ33934034-9C5BED5F-0023-45CD-8F1F-B7051F8490D3Q34014960-73801160-AADC-42A9-8EDE-D8EE5BD74D01Q34015988-E659BD2B-1436-4980-880F-B6B401DA73A4Q34057901-1CCB4B77-A989-4747-997E-CECD262A5FDDQ34247261-18442B3C-BF78-4274-BBBF-34261DC9D67FQ34261999-38C346BE-0793-4120-AD36-8A50913CDCF7Q34457808-88DB91C8-06BB-426C-948C-742D9F51792FQ35499344-5A3FDD16-F8D2-4474-8E93-4D8727B08FE0Q35531454-49C811C5-C1BE-4168-9FBB-3A5586607A06Q35660187-F8541D00-ABA3-41DF-8C4F-16E60F73BE26Q35857387-2AE302BE-D558-4AA6-8E18-C66072E38C84Q35901171-86DDA8AF-CA89-4CA9-9C4B-7DFAC313A74FQ35914462-1E386E30-D6D8-49FF-9223-4DB4A7B74179Q36315144-632DA5F4-AF06-4183-8497-1733F84FE4D2Q36456720-C3F523EE-5577-444A-A784-D8405C34ED66Q36483886-E6093147-6E03-437E-8309-2A2A89740223Q36496355-7005DAFF-2E56-413A-9644-8203AFDEB574Q36498144-96D8C27F-388D-48FD-A96F-01F6329943A0Q36650501-BCFAC2BE-20CA-4BE5-A869-94C0DD538611Q36702376-BD36DE24-5E4B-474E-B844-953835258232
P2860
Vaccine efficacy in senescent mice challenged with recombinant SARS-CoV bearing epidemic and zoonotic spike variants
description
2006 nî lūn-bûn
@nan
2006 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2006 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
name
Vaccine efficacy in senescent ...... ic and zoonotic spike variants
@ast
Vaccine efficacy in senescent ...... ic and zoonotic spike variants
@en
Vaccine efficacy in senescent ...... ic and zoonotic spike variants
@nl
type
label
Vaccine efficacy in senescent ...... ic and zoonotic spike variants
@ast
Vaccine efficacy in senescent ...... ic and zoonotic spike variants
@en
Vaccine efficacy in senescent ...... ic and zoonotic spike variants
@nl
prefLabel
Vaccine efficacy in senescent ...... ic and zoonotic spike variants
@ast
Vaccine efficacy in senescent ...... ic and zoonotic spike variants
@en
Vaccine efficacy in senescent ...... ic and zoonotic spike variants
@nl
P2093
P2860
P921
P1433
P1476
Vaccine efficacy in senescent ...... ic and zoonotic spike variants
@en
P2093
Alan Whitmore
Boyd Yount
Damon Deming
Eric Donaldson
Jack Harkema
Kristopher Curtis
Mehul Suthar
Nancy Davis
P2860
P356
10.1371/JOURNAL.PMED.0030525
P407
P577
2006-12-01T00:00:00Z